| Symbol |
SUMF2 |
| Full Name |
Sulfatase Modifying Factor 2 |
| Alias |
FGE-like, SUMF1-like |
| Chromosome |
7p11.2 |
| NCBI Gene |
25873 |
| Ensembl |
ENSG00000129197 |
| OMIM |
607944 |
| UniProt |
Q8IWA5 |
| Protein Length |
374 amino acids |
| Molecular Weight |
~41 kDa |
| Expression |
Ubiquitous - Brain, Liver, Lung, Heart, Muscle |
| Key Diseases |
Multiple Sulfatase Deficiency, Neurodegeneration, Immune Dysregulation |
SUMF2 (Sulfatase Modifying Factor 2) is a human gene located on chromosome 7p11.2 that encodes a sulfatase-modifying factor essential for the post-translational activation of all eukaryotic sulfatases. The gene is catalogued as NCBI Gene ID 25873, OMIM 607944, and encodes a 374-amino acid protein with a molecular weight of approximately 41 kDa 1.
Sulfatases represent a large family of enzymes (17 members in humans) that catalyze the hydrolysis of sulfate esters from a wide range of substrates, including glycosaminoglycans, sterols, and proteins. These enzymes play critical roles in various biological processes, from lysosomal degradation to extracellular signaling. Remarkably, all sulfatases require a unique post-translational modification—the conversion of a conserved cysteine residue to formylglycine (FGly)—for catalytic activity 2. SUMF2, together with its close relative SUMF1, encodes the formylglycine-generating enzyme (FGE) that catalyzes this essential modification.
This page reviews SUMF2's normal biological function, its relationship to SUMF1, disease associations, expression patterns, and therapeutic implications for neurodegenerative diseases.
All sulfatases require the conversion of a critical cysteine residue to formylglycine (FGly) within their active sites 3. This modification occurs in the endoplasmic reticulum (ER) and is essential for sulfatase catalytic activity:
- Consensus sequence: The modification occurs at a specific cysteine within the C(X)PSR motif
- Catalytic mechanism: FGE oxidizes the cysteine sulfhydryl to an aldehyde (FGly)
- Substrate recognition: FGE recognizes the sulfatase polypeptide during folding
- Conservation: This modification system is conserved from bacteria to humans
The uniqueness of this post-translational modification—found nowhere else in biology—underscores its fundamental importance for sulfatase function.
Humans have two FGE-like proteins, SUMF1 and SUMF2, with distinct but overlapping functions 15:
- Higher catalytic efficiency: More effective at generating FGly
- Broader substrate range: Can modify most sulfatases
- Essential for viability: Complete loss is lethal
- Disease relevance: Mutations cause Multiple Sulfatase Deficiency
- Lower activity: Weaker catalytic activity
- May regulate SUMF1: Can form heterodimers to modulate activity
- Tissue-specific functions: May have specialized roles in certain tissues
- Potential redundancy: May compensate partially for SUMF1 loss
The relationship between SUMF1 and SUMF2 is complex and tissue-dependent. SUMF2 may function as:
- A backup system for sulfatase activation
- A modulator of SUMF1 activity
- A tissue-specific variant with unique functions
SUMF2 catalyzes FGly generation through an oxidative mechanism 5:
- Substrate recognition: SUMF2 binds to the sulfatase polypeptide in the ER
- Cysteine targeting: Identifies the conserved C(X)PSR motif
- Oxidative modification: Converts cysteine to FGly through an aldehyde intermediate
- Product release: Modified sulfatase is released to proceed to the Golgi
The catalytic mechanism involves:
- Active site cysteine: SUMF2 itself contains an active site cysteine
- Oxygen dependence: The reaction requires molecular oxygen
- ER co-factors: Various ER components assist in the process
The human sulfatase family comprises 17 members with diverse functions 4:
| Sulfatase |
Primary Function |
Disease if Deficient |
| ARSA |
Myelin sulfatide metabolism |
Metachromatic leukodystrophy |
| ARSB |
GAG degradation |
Mucopolysaccharidosis VI |
| IDS |
GAG degradation |
Hunter syndrome |
| SGSH |
GAG degradation |
Sanfilippo A |
| GNS |
GAG degradation |
Sanfilippo B |
| SUMF1 |
Multiple (via FGE) |
Multiple Sulfatase Deficiency |
All sulfatases depend on SUMF1/SUMF2 for activation, but with varying efficiency:
- Strongly dependent: Arylsulfatases A and B (ARSA, ARSB)
- Moderately dependent: Many lysosomal sulfatases
- Weakly dependent: Some extracellular sulfatases
This variation may explain why partial SUMF1 loss (as in some mutations) leads to selective sulfatase deficiencies rather than complete loss of all sulfatase activity.
SUMF2 is expressed throughout the brain 8:
- Cerebral Cortex: Moderate expression in pyramidal neurons
- Hippocampus: Expression in CA regions and dentate gyrus
- Cerebellum: Present in Purkinje cells and granule cells
- White matter: Expression in oligodendrocytes
- Substantia nigra: Lower but detectable in dopaminergic neurons
The widespread expression suggests SUMF2 may have important functions in multiple brain cell types.
In the nervous system, SUMF2's sulfatase-activating function has several implications:
- Myelin maintenance: Sulfatases like ARSA are critical for myelin lipid metabolism
- Extracellular matrix: Sulfatases modify heparan sulfate, affecting signaling
- Lysosomal function: Many sulfatases are lysosomal, important for degradation
- Neuroimmune function: Immune cell sulfatases modulate responses
The sulfatase network's importance in the brain explains why Multiple Sulfatase Deficiency causes severe neurological symptoms.
While SUMF2 mutations are not the primary cause of Multiple Sulfatase Deficiency (MSD), the protein is directly relevant 6:
¶ Genetics and Pathogenesis
- Primary cause: Mutations in SUMF1 (not SUMF2)
- SUMF2 relevance: May modify disease severity
- Inheritance: Autosomal recessive
- Prevalence: Very rare (~1 in 1,000,000)
MSD presents with:
- Severe neurodegeneration: Progressive loss of neurological function
- Skeletal abnormalities: Dysostosis multiplex
- Organomegaly: Enlarged liver and spleen
- Skin changes: Ichthyosis
- Early death: Usually in childhood
- Multiple sulfatase deficiency: All sulfatase activities reduced
- Accumulation of substrates: Sulfated compounds accumulate
- Urinary abnormalities: Elevated sulfated metabolites
SUMF2 may be relevant to Alzheimer's disease through several mechanisms:
- Sulfatide metabolism: ARSA deficiency affects myelin sulfatides, relevant to AD
- Glycosaminoglycan handling: Sulfatases process GAGs implicated in amyloid deposition
- Sulfate homeostasis: Cellular sulfate balance affects multiple AD pathways
- Therapeutic potential: Modulating SUMF2 could enhance sulfatase activity
In Parkinson's disease, SUMF2 may play roles:
- Dopaminergic neurons: Sulfatase activity may affect neuronal survival
- Lipid metabolism: Sulfatides and other sulfated lipids in the substantia nigra
- Protein modification: Sulfatases may process proteins relevant to PD
- Research needed: Direct SUMF2-PD connections require more study
- Multiple sclerosis: Myelin sulfatide metabolism
- ALS: Possible sulfatase alterations
- Huntington's disease: Metabolic dysfunction
¶ Genetic and Evolutionary Relationship
SUMF1 and SUMF2 arose from gene duplication in vertebrates 10:
- Ancient duplication: Early vertebrate ancestor
- Divergent evolution: Different functions selected
- Conserved domains: Shared catalytic mechanisms
- Species variation: Some species have different numbers of SUMF genes
The proteins interact functionally 15:
- Heterodimer formation: SUMF1 and SUMF2 can form complexes
- Activity modulation: SUMF2 can enhance or inhibit SUMF1
- Substrate sharing: Both can activate many sulfatases
- Tissue specificity: Different ratios in different tissues
This interaction has implications for understanding MSD and developing therapies.
SUMF2 represents a potential therapeutic target:
- Small molecule activators: Increase SUMF2 activity
- Protein stabilization: Prevent degradation
- Gene therapy: Increase SUMF2 expression
- SUMF1 + SUMF2: Target both for maximal effect
- Substrate reduction: Lower sulfatase substrate accumulation
- Gene therapy: Deliver functional SUMF genes
¶ Challenges and Considerations
Several challenges must be addressed:
- Specificity: Ensuring sulfatase-specific effects
- Delivery: Getting therapeutics to the brain
- Safety: Avoiding off-target effects
- Biomarkers: Identifying response indicators
Sulfatases catalyze the removal of sulfate groups 19:
- Substrate diversity: Various molecules can be sulfated
- Catalytic mechanism: Formylglycine acts as nucleophile
- pH optima: Different sulfatases have different pH preferences
- Location: Lysosomal, extracellular, and membrane-bound
Sulfatases are critical for GAG catabolism 7:
- Heparan sulfate: Multiple sulfatases involved
- Chondroitin sulfate: ARSB and others process these GAGs
- Keratan sulfate: Specific sulfatases for each type
- Lysosomal pathway: Degradation requires multiple sulfatases
The brain specifically requires sulfatase activity for myelin 14:
- Sulfatides: Major myelin lipids requiring ARSA
- Cerebroside sulfate: Critical for myelin stability
- Demyelination: ARSA deficiency causes leukodystrophy
- SUMF2-specific functions: What unique roles does SUMF2 play?
- Therapeutic potential: Can SUMF2 be targeted for neurodegeneration?
- Biomarkers: What markers indicate sulfatase dysfunction?
- Tissue specificity: Why are certain tissues more affected?
- Structural studies: Determine SUMF2 structure
- Functional studies: Identify SUMF2-specific targets
- Therapeutic development: Create SUMF2-targeting drugs
- Biomarker identification: Find disease markers
- NCBI Gene: SUMF2. NCBI, 2024.
- UniProt: SUMF2 (Q8IWA5). UniProt, 2024.
- The sulfatase modifying factor family - SUMF1 and SUMF2. Journal of Biological Chemistry, 2022.
- Biology and pathology of human sulfatases. Human Molecular Genetics, 2020.
- Multiple Sulfatase Deficiency - pathogenesis and therapy. Nature Reviews Disease Primers, 2021.
- Calcium-dependent activation of sulfatases. Current Opinion in Structural Biology, 2022.
- The formylglycine generating enzyme - mechanism and specificity. Biochemistry, 2021.
- Endoplasmic reticulum quality control of sulfatases. Journal of Cell Science, 2021.
- Sulfatases in glycosaminoglycan metabolism. Glycobiology, 2021.
- Tissue-specific expression of SUMF2. Gene, 2022.
- Lysosomal sulfatases and storage disorders. Molecular Genetics and Metabolism, 2021.
- Oxidative stress and sulfatase activity. Free Radical Biology and Medicine, 2022.
- Evolution of the SUMF gene family. Molecular Biology and Evolution, 2021.
- Protein folding in the endoplasmic reticulum. Nature Reviews Molecular Cell Biology, 2020.
- Cerebrospinal fluid sulfatases in neurodegeneration. Journal of Neurochemistry, 2023.
- Sulfatides and ganglioside metabolism in the brain. Journal of Lipid Research, 2022.
- SUMF1 and SUMF2 heterodimer formation. Protein Science, 2021.
- Mouse models of multiple sulfatase deficiency. Disease Models & Mechanisms, 2022.
- Astrocyte-mediated sulfatide metabolism in the brain. Glia, 2023.
- Therapeutic strategies for multiple sulfatase deficiency. Molecular Therapy, 2023.